249 related articles for article (PubMed ID: 20021873)
21. Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Yamanaka K; Hatano E; Kitamura K; Iida T; Ishii T; Machimito T; Taura K; Yasuchika K; Isoda H; Shibata T; Uemoto S
J Gastroenterol; 2012 Mar; 47(3):343-6. PubMed ID: 22183859
[TBL] [Abstract][Full Text] [Related]
22. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
24. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
Cai R; Song R; Pang P; Yan Y; Liao Y; Zhou C; Wang S; Zhou X; Wang H; Zhang H; Sun H; Ma H
BMC Cancer; 2017 Nov; 17(1):714. PubMed ID: 29110700
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
[TBL] [Abstract][Full Text] [Related]
26. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
[TBL] [Abstract][Full Text] [Related]
27. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
28. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
[TBL] [Abstract][Full Text] [Related]
29. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Oncology; 2014; 87 Suppl 1():32-6. PubMed ID: 25427731
[TBL] [Abstract][Full Text] [Related]
30. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
Huang YK; Yen CL; Shiu SI; Lee SW; Chang PY; Yeh HZ; Lee TY
PLoS One; 2017; 12(11):e0188999. PubMed ID: 29190692
[TBL] [Abstract][Full Text] [Related]
31. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
33. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Lee TY; Lin CC; Chen CY; Wang TE; Lo GH; Chang CS; Chao Y
Medicine (Baltimore); 2017 Sep; 96(37):e7655. PubMed ID: 28906355
[TBL] [Abstract][Full Text] [Related]
34. [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
Takeda Y; Nakahira S; Takeno A; Suzuki R; Nakata K; Okishiro M; Egawa C; Okamura S; Miki H; Kato T; Takatsuka Y; Tamura S
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2496-8. PubMed ID: 22202425
[TBL] [Abstract][Full Text] [Related]
35. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
37. [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
Watanabe Y; Nakaba H; Taniguchi E; Kikkawa H; Tamagawa H; Sasaki M; Kitayama T; Doi Y; Oguchi Y
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2110-2. PubMed ID: 25731439
[TBL] [Abstract][Full Text] [Related]
38. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
39. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
